Related Experiment Video
Updated: Jun 11, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Ironing out MAFLD: Therapeutic targeting of liver ferroptosis
1Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Suzhou Medical College of Soochow University, Soochow University, Suzhou, Jiangsu, China.
Abstract:
Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with iron metabolism disorders and ferroptosis, but the mechanisms underlying this association remain unclear. Fudi Wang's group1 used animal models, human cohorts, and multi-omics data to demonstrate the role of iron imbalance in MAFLD and the therapeutic potential of the iron chelator FerroTerminator 1 (FOT1).
Insights
Metabolic dysfunction-associated fatty liver disease (MAFLD) involves iron problems and cell death. Researchers found that an iron chelator, FerroTerminator 1 (FOT1), may treat MAFLD by correcting iron imbalance.
Area of Science:
- Hepatology
- Metabolic Disorders
- Iron Metabolism
Background:
- Metabolic dysfunction-associated fatty liver disease (MAFLD) is linked to iron dysregulation.
- The precise mechanisms connecting iron metabolism disorders and ferroptosis in MAFLD are not fully understood.
Purpose of the Study:
- To elucidate the role of iron imbalance in the pathogenesis of MAFLD.
- To investigate the therapeutic efficacy of the novel iron chelator, FerroTerminator 1 (FOT1), in MAFLD.
Main Methods:
- Utilized a combination of animal models and human cohorts.
- Employed multi-omics data analysis to explore molecular mechanisms.
- Assessed the effects of FOT1 on iron homeostasis and liver pathology.
Main Results:
- Demonstrated a significant association between iron imbalance and MAFLD progression.
- Confirmed the iron-chelating properties of FOT1.
- Showed that FOT1 administration ameliorated MAFLD phenotypes in experimental models.
Conclusions:
- Iron dysregulation is a key factor in MAFLD.
- FerroTerminator 1 (FOT1) shows promise as a therapeutic agent for MAFLD by targeting iron imbalance and ferroptosis.
